Skip to main content
    M

    MoonLake Immunotherapeutics (MLTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.73
    -0.77 (-6.16%)

    Market Cap: $1.06B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MoonLake Immunotherapeutics (MLTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    MoonLake Immunotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$230.32M, operating cash flow was -$196.01M and free cash flow was -$196.04M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$79.55M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $244.83M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$202.86M$112.77M$31.80M$42.05M$0$0
    Operating income-$244.83M-$143.09M-$54.12M-$65.06M-$4.57M-$105.75K
    Net income-$230.32M-$121.24M-$44.08M-$64.51M-$4.54M-$90.84K
    EBITDA-$219.85M-$119.58M-$43.62M-$64.30M-$4.57M-$90.84K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$101.85K$0$0$0$19.74K
    Gross profit$0$0$0-$751.00K$0$0$0$50.92K$0$0$0$16.45K
    Operating income-$79.85M-$61.66M-$70.02M-$65.22M-$71.43M-$60.70M-$47.48M-$49.58M-$43.11M-$30.58M-$19.82M-$15.03M
    Net income-$79.55M-$61.80M-$69.71M-$63.02M-$70.69M-$56.05M-$40.56M-$46.40M-$36.11M-$24.76M-$13.97M-$7.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $75.33M by $259.18M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$424.43M$477.93M$526.54M$76.84M$9.68M$116.63M
    Current assets$421.69M$474.29M$514.17M$76.51M$9.64M$1.62M
    Cash and equivalents$334.52M$180.43M$451.17M$39.51M$8.04M$1.34M
    Total liabilities$119.95M$24.54M$13.05M$8.08M$21.33M$4.15M
    Short-term debt$1.23M$1.37M$1.20M$153.63K$15.00M$58.06K
    Long-term debt$74.10M$0N/AN/AN/AN/A
    Shareholder equity$304.48M$446.82M$495.68M$48.90M-$11.65M-$2.52M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$540.72M$573.95M$400.37M$424.43M$414.33M$460.10M$511.26M$477.93M$518.21M$544.88M$564.12M$526.54M
    Total liabilities$159.09M$145.75M$146.35M$119.95M$123.14M$102.15M$98.68M$24.54M$22.71M$14.85M$11.73M$13.05M
    Cash and equivalents$379.70M$477.90M$298.49M$334.52M$350.74M$306.68M$271.57M$180.43M$375.66M$342.79M$458.44M$451.17M
    Shareholder equity$381.63M$428.19M$254.02M$304.48M$288.91M$353.73M$407.52M$446.83M$488.20M$520.66M$542.55M$495.68M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$196.01M-$116.59M-$42.78M-$55.89M-$611.07K-$316.69K
    Capital expenditures$35.00K$520.00K$284.00K$16.01K$50.71K$0
    Free cash flow-$196.04M-$117.11M-$43.06M-$55.91M-$661.78K-$316.69K
    Investing cash flow$202.99M-$205.60M-$25.18M-$32.34M$0-$115.00M
    Financing cash flow$146.00M$51.31M$479.70M$119.69M-$58.06K$116.65M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$63.40M-$55.56M-$66.29M-$58.79M-$44.54M-$54.53M-$38.14M-$48.47M-$25.28M-$27.89M-$14.95M-$12.34M
    Capital expendituresN/AN/A$0$0$0$0$35.00K$176.00K$132.00K$3$212.00K$284.00K
    Free cash flowN/AN/A-$66.29M-$58.79M-$44.54M-$54.53M-$38.17M-$48.65M-$25.41M-$27.89M-$15.16M-$12.63M
    Last 12 quarters

    Frequently Asked Questions About MLTX

    What is MoonLake Immunotherapeutics' annual revenue?

    MoonLake Immunotherapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is MoonLake Immunotherapeutics profitable?

    No. MoonLake Immunotherapeutics reported net income of -$230.32M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MLTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$196.01M minus capital expenditures of $35.00K produced free cash flow of -$196.04M.

    How much debt does MoonLake Immunotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $74.10M, short-term debt of $1.23M and cash and equivalents of $334.52M.